CA1146859A
Expired / Lapsed
CA
⏱️ 0.0 years remaining
Pharmaceutical preparations containing zinc
Assignee: Novartis AG
•
Filing: 1979-11-30
•
Granted: 1983-05-24
•
Expires: 1999-11-30
Abstract
Abstract New Pharmaceutical preparations containing zinc. Abstract of the Disclosure The invention relates to new pharmaceutical preparations containing zinc for topical administration in the treatment of in-fections caused by herpes viruses, especially those which have been caused by herpes virus hominis, for example of herpes genitalis and herpes dermatitis. The preparations contain as antiviral agent an effective antiviral combination of a pharmaceutically acceptable salt of an acid sulphated polysaccharide or acid sulphated polymer, and zinc ions, and may further contain polyoxyethylene sorbitan mono-laurate and/or -monooleate. They are usual types of preparations for topical administration such as creams, ointments, tinctures, aqueous solutions and, especially, gels.
Inventors
- 👤 Bohumir Lukas
- 👤 Walter Wiesendanger
- 👤 Karl H. Schmidt-Ruppin
Bibliographic Details
Application Number
—
Jurisdiction
CA
Data Source
google_patents
Last Synchronized
2026-10-28 22:05
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/24; A61K33/30; A61P; A61P17/00; A61P31/00; A61P31/12
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
42 words
Pharmaceutical preparation containing zinc for topical ad-ministration which contains an effective antiviral combination of a pharmaceutically acceptable salt of an acid sulphated polysaccharide or acid sulphated polymer and zinc ions in a ratio of 1 mg to 0.18 up to 18 mg.
Claim 2
Dependent Claim
42 words
Pharmaceutical preparation containing zinc for topical ad-ministration which contains an effective antiviral combination of a pharmaceutically acceptable salt of an acid sulphated polysaccharide or acid sulphated polymer and zinc ions in a ratio of 1 mg to 0.18 up to 18 mg.
Claim 3
Dependent Claim
18 words
Pharmaceutical preparation according to claim 1 in the form of a gel, cream, ointment, tincture or aqueous solution.
Claim 4
Dependent Claim
24 words
Pharmaceutical preparation according to claim 1 which additionally contains at least one surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate.
Claim 5
Dependent Claim
37 words
Pharmaceutical preparation according to claim 1 which contains a pharmaceutically acceptable salt of an acid sulphated poly-saccharide or acid sulphated polymer and zinc ions in a ratio of 1 mg to 0.18 mg up to 4.5 mg.
Claim 6
Dependent Claim
29 words
Pharmaceutical preparation according to claim 1 which con-tains a pharmaceutically acceptable salt of heparin and zinc ions in a ratio of 160 IU up to 0.18 to 18 mg.
Claim 7
Dependent Claim
38 words
Pharmaceutical preparation according to claim 1 which con-tains, per gram or millilitre, 0.1 to 5 mg of a pharmaceutically acceptable salt of an acid sulphated polysaccharide or acid sul-phated polymer and 0.18 to 18 mg of zinc ions.
Claim 8
Dependent Claim
38 words
Pharmaceutical preparation according to claim 1 which contains, per gram or millilitre, 0.25 to 3 mg of a pharmaceuti-cally acceptable salt of an acid sulphated polysaccharide or acid sulphated polymer and 0.18 to 18 mg of zinc ions.
Claim 9
Dependent Claim
31 words
Pharmaceutical preparation according to claim 1 which con-tains, per gram or millilitre, 16 to 800 IU of a pharmaceutically acceptable salt of heparin and 0.18 to 18 mg of zinc ions.
Claim 10
Dependent Claim
31 words
Pharmaceutical preparation according to claim 8 which con-tains, per gram or millilitre, 40 to 480 IU of a pharmaceutically acceptable salt of heparin and 0.18 to 18 mg of zinc ions.
Claim 11
Dependent Claim
27 words
Pharmaceutical preparation according to claim 8 which contains 80 to 320 IU of a pharmaceutically acceptable salt of heparin, and 0.45 to 4.5 mg of zinc ions.
Claim 12
Dependent Claim
24 words
Pharmaceutical preparation according to any one of claims 5, 9 and 10, which contains the sodium salt of heparin as its pharmaceutically acceptable salt.
Claim 13
Dependent Claim
32 words
Pharmaceutical preparation according to claim 1 which con-tains, per gram or millilitre, 0.1 to 5.0 mg of a pharmaceutically acceptable salt of dextran sulphate and 0.18 to 18 mg of zinc ions.
Claim 14
Dependent Claim
32 words
Pharmaceutical preparation according to claim 12 which con-tains, per gram or millilitre, 0.25 to 3.0 mg of a pharmaceutically acceptable salt of dextran sulphate and 0.18 to 18 mg of zinc ions.
Claim 15
Dependent Claim
32 words
Pharmaceutical preparation according to claim 12 which con-tains, per gram or millilitre, 0.25 to 2.0 mg of a pharmaceutically acceptable salt of dextran sulphate and 0.45 to 4.5 mg of zinc ions.
Claim 16
Dependent Claim
32 words
Pharmaceutical preparation according to claim 1 which con-tains, per gram or millilitre, 0.1 to 5.0 mg of a pharmaceutically acceptable salt of polyvinyl sulphate and 0.18 to 18 mg of zinc ions.
Claim 17
Dependent Claim
32 words
Pharmaceutical preparation according to claim 15 which con-tains, per gram or millilitre, 0.25 to 3.0 mg of a pharmaceutically acceptable salt of polyvinyl sulphate and 0.18 to 18 mg of zinc ions.
Claim 18
Dependent Claim
32 words
Pharmaceutical preparation according to claim 15 which con-tains, per gram or millilitre, 0.25 to 2.0 mg of a pharmaceutically acceptable salt of polyvinyl sulphate and 0.45 to 4.5 mg of zinc ions.
Claim 19
Dependent Claim
31 words
Pharmaceutical preparation according to any one of claims 1, 4 and 6, which contains sodium or potassium salt as pharmaceutically acceptable salt of an acid sulphated polysaccharide or acid sulphated polymer.
Claim 20
Dependent Claim
28 words
Pharmaceutical preparation according to any one of claims 1, 4 and 6 to which the zinc ions are added in the form of ZnSO4.7H2O as dissociable zinc compound.
Claim 21
Dependent Claim
37 words
Pharmaceutical preparation according to any one of claims 1, 4 and 6 which additionally contains, per gram or millilitre, 0.2 to 50 mg of a surface active agent selected from polyoxyethylene sorbi-tan monolaurate and polyoxyethylene sorbitan monooleate.
Claim 22
Dependent Claim
37 words
Pharmaceutical preparation according to any one of claims 1, 4 and 6 which additionally contains, per gram or millilitre, 0.5 to 10 mg of a surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.